Areas of ongoing development include expanding the provider network to serve additional geographic markets, evaluating new formulations and medications as pharmaceutical innovation advances, enhancing digital health tools integrating wearables and tracking technologies, developing additional patient support resources including nutritional and behavioral health services, and refining treatment protocols based on real-world outcome data from the patient population
For inquiries related to Novo Nordisk products, distribution, or sourcing support across Uttar Pradesh, Bihar, Madhya Pradesh, and Rajasthan, please get in touch with us
And Im Dan Friedell
I love itI already lost 11 lbs in just 1 month Working well for 1st month Lost 7 pounds in a little over a week
Compared to bariatric outcomes, for GLP-1 agonists the effect of weight loss are less, but still significant: Semaglutide 2.4 mg: 1218% mean weight loss at 1 year in adherent cohorts, often around 1317% in practice Tirzepatide 1015 mg: 1620% weight loss at 72 weeks
However, their rising popularity for weight management, including off-label use, has contributed to a supply shortage, leaving many patients unable to access these medications